Trump Administration Deal to Lower GLP-1 Drug Costs Offers Relief to Patients Facing Coverage Loss
The Trump administration announced a deal today that will lower the direct-to-consumer price of popular weight-loss drugs like Zepbound and Wegovy to an average of $350 a month, potentially dropping to around $150, as many insurers move to restrict coverage for these medications.
The agreement with Eli Lilly and Novo Nordisk expands access to Medicare and Medicaid, programs that currently offer limited coverage for these drugs. For patients like Sarah Brophy of Topsfield, Massachusetts, who currently pays a $10 monthly co-pay, the change offers a crucial alternative as her insurer, Harvard Pilgrim Health Care, plans to eliminate GLP-1 coverage for weight loss next year. “Believe me, I would have loved for it to just stay $10,” Brophy said, “but paying $350 a month is better than $500. That would put a strain on our finances.”
Several major insurers and employers, citing unsustainable costs – often ranging from $950 to $1,400 per month – are scaling back or eliminating GLP-1 coverage. Massachusetts, which previously had the highest rate of insured individuals covered for obesity medications at nearly 68 percent, is now seeing a shift. Boston University and UMass Memorial Health will stop covering these drugs for weight loss in the new year, while others, like Boston College and Beth Israel Lahey Health, will continue coverage. The rising cost of these medications has contributed to operating losses for insurers like Blue Cross Blue Shield of Massachusetts and Point32Health, leading to layoffs and employee buyouts. For more information on the impact of prescription drug costs, see Kaiser Family Foundation’s research on health costs.
Health experts caution that medication is only one component of successful weight management, emphasizing the importance of nutrition and exercise. Dr. Rocio Salas-Whalen, author of “Weightless,” noted that responsible access to these drugs is paramount, especially given projections that half the world’s population will be obese by 2030. The administration will offer the drugs through a new website, TrumpRx.gov. This development comes as the Health Business Group predicts employers will increasingly rely on direct-to-consumer options as insurance coverage wanes.
Officials stated that the administration will continue to monitor the program and work with manufacturers to ensure continued access and affordability for patients.
